Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

T2 Biosystems Expects Q4 2024 sepsis product revenue to be $2.5M to $3.5M.

Author: Benzinga Newsdesk | November 14, 2024 05:15pm

T2 Biosystems (NASDAQ:TTOO) .

Posted In: TTOO